The U.S. Federal Trade Commission (FTC) has blessed Becton, Dickinson and Company's (BDX) acquisition of C.R. Bard (BCR +0.3%) contingent on BD divesting its soft tissue core needle biopsy portfolio and Bard divesting its Aspira line of tunneled home drainage catheters and accessories.
BD says the deal should close next week.
Previously: Becton Dickinson buying C.R. Bard for $24B (April 23)
Subscribe for full text news in your inbox